聽is a collaboration between聽听补苍诲听, focused on the union of 汤头条鈥檚 innovative life science discovery efforts and Deerfield鈥檚 commitment to accelerating state-of-the-art drug development. Deerfield will fund Ancora Innovation with up to $65 million to pursue novel therapeutics and will provide additional capital to fund successful start-up companies that spin out of Ancora.
Ancora Innovations is currently requesting proposals to develop innovative therapeutic strategies to rare genetic diseases.
All rare diseases with a known genetic cause that can be diagnosed with the aid of clinical sequencing are eligible. 聽Preference is given to diseases with existing patient communities and clear clinical measures.
Each therapeutic discovery project supported by this funding opportunity must focus on a clear therapeutic hypothesis enabled by genetic and biological understanding of disease pathophysiology with cellular and in vivo models available. Existing therapeutic candidates are not required.
Therapeutics of interest include small molecules, biopharmaceuticals, and gene therapies.
Interested faculty should contact聽Margaret Read聽to learn more about next steps and formal submission.
